Recent developments in U.S. federal marijuana policy have prompted questions from employers about whether workplace drug testing requirements may be changing. While there has been movement at the federal level regarding marijuana classification, there is currently no impact on Department of Transportation (DOT) testing protocols or workplace drug testing requirements.
Background on the Policy Change
On December 18, 2025, U.S. President Donald Trump signed an executive order directing federal authorities to reclassify marijuana from a Schedule I to a less restrictive Schedule III controlled substance under U.S. federal law.
Following that directive, on April 22, 2026, the U.S. Department of Justice, through the Drug Enforcement Administration, issued a final order reclassifying certain marijuana substances from Schedule I to Schedule III under the Controlled Substances Act.
This update represents a narrow regulatory change and does not alter current workplace or DOT drug testing requirements.
What Has Changed
The rescheduling applies only to:
FDA-approved drug products containing marijuana
Marijuana handled under a qualifying state medical marijuana licence
This means that only certain regulated medical marijuana products are affected by the reclassification.
What Has Not Changed
The majority of marijuana-related substances in the United States remain classified as Schedule I, including:
Unlicensed, non-medical, or recreational marijuana
Bulk marijuana and most marijuana extracts
Synthetic THC
Hemp, which remains unaffected under current U.S. federal definitions
For employers, this means the broader legal status of marijuana under federal law remains largely unchanged.
What This Means for Employers
This update does not change current workplace or DOT drug testing requirements.
Employers should continue following existing policies and regulatory requirements:
U.S. Department of Transportation regulated testing programs remain unchanged
Drug-free workplace policies do not need to be revised at this time
Marijuana remains a controlled substance under U.S. federal law outside limited medical contexts
This change does not affect how Medical Review Officers (MROs) assess THC test results
For organizations operating safety-sensitive workplaces, current testing protocols and impairment management practices remain fully in effect.
Important Considerations for Canadian Employers
This regulatory change applies only in the United States and does not affect Canadian laws.
Drug classification frameworks differ between the U.S. and Canada. While future U.S. regulatory developments may eventually influence how medical cannabis use is considered in workplace testing, there are no changes to Canadian testing practices or MRO processes at this time.
If U.S. rules evolve further, MRO review processes may begin to resemble Canadian practices, where approved medical cannabis use can be considered while still addressing fitness-for-duty requirements in safety-sensitive roles.
Industry Response
Industry groups, including the National Drug and Alcohol Screening Association, have emphasized the importance of maintaining clear regulatory guidance to ensure transportation safety is not compromised by this change.
This reinforces the need for employers to remain informed while continuing to prioritize workplace safety and impairment prevention.
While this policy update is noteworthy, it does not require any immediate action from employers.
Organizations should continue to:
Maintain current workplace drug testing programs
Follow existing DOT and workplace regulatory requirements
Monitor for future federal guidance
At DriverCheck, we will continue monitoring regulatory developments and keep clients informed of any future changes that may impact workplace testing programs.
Maintaining workplace safety and managing impairment risk remain critical priorities, and we are committed to helping employers navigate these evolving regulatory landscapes.
Related Services: